During the past quarter decade, the rapid expansion health information through the institution of electronic health records, the implementation new technologies for large-scale generation of multi-omic and imaging data, and development of new statistical and computational methodologies for cancer research has led to a recognition of the critical need for participation of quantitative scientists in the research process and a higher standard for what constitutes acceptable scientific evidence in a study. The GI SPORE will conduct large-scale studies and generate substantial quantities of complex biological and biomedical data. Ensuring that the SOPRE's research projects arrive at robust and statistically significant conclusions. The Biostatistics and Bioinformatics Core includes leading quantitative research scientists who will work with SPORE personnel to assure that the research carried out meets the prevailing and emerging research standards and adapts as new technologies develop and are introduced into the scientific research program. This support will be provided by establishing, maintaining, and supporting collaborative relationships that will ensure that Core members are integrated members of the research teams and provide appropriate statistical and computational support for all GI cancer SPORE investigators. This will include consultation and collaboration on all aspects of study design, database development and quality control, and analysis and interpretation of data.

Public Health Relevance

The Biostatistics and Bioinformatics Core will provide support for the research mission of the GI SPORE by assisting the members of the Programs and other Cores in the design of their experiments and the analysis and interpretation of the resulting data. The Core personnel represent leading experts in biostatistics and bioinformatics and will use modern, advanced methods to assure the conclusions emerging from the SPORE are robustly supported by the underlying data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA127003-11A1
Application #
9792055
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2007-04-01
Project End
2024-05-31
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
11
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Babic, A; Schnure, N; Neupane, N P et al. (2018) Plasma inflammatory cytokines and survival of pancreatic cancer patients. Clin Transl Gastroenterol 9:145
Lopes-Ramos, Camila M; Kuijjer, Marieke L; Ogino, Shuji et al. (2018) Gene Regulatory Network Analysis Identifies Sex-Linked Differences in Colon Cancer Drug Metabolism. Cancer Res 78:5538-5547
Van Blarigan, Erin L; Ou, Fang-Shu; Niedzwiecki, Donna et al. (2018) Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:1227-1230
Patra, Krushna C; Kato, Yasutaka; Mizukami, Yusuke et al. (2018) Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol 20:811-822
Katona, Bryson W; Yurgelun, Matthew B; Garber, Judy E et al. (2018) A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genet Med 20:1324-1327
Jeon, Jihyoun; Du, Mengmeng; Schoen, Robert E et al. (2018) Determining Risk of Colorectal Cancer and Starting Age of Screening Based on Lifestyle, Environmental, and Genetic Factors. Gastroenterology 154:2152-2164.e19
Kosumi, Keisuke; Hamada, Tsuyoshi; Koh, Hideo et al. (2018) The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. Am J Pathol 188:2839-2852
Aguirre, Andrew J (2018) Refining Classification of Pancreatic Cancer Subtypes to Improve Clinical Care. Gastroenterology 155:1689-1691
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Wang, Xiaoliang; Chan, Andrew T; Slattery, Martha L et al. (2018) Influence of Smoking, Body Mass Index, and Other Factors on the Preventive Effect of Nonsteroidal Anti-Inflammatory Drugs on Colorectal Cancer Risk. Cancer Res 78:4790-4799

Showing the most recent 10 out of 590 publications